{"id":"W3011210265","doi":"10.1200/jco.2006.24.18_suppl.3508","title":"Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Clinical endpoint; Irinotecan; Placebo; Bevacizumab; Interim analysis; Adverse effect; Progression-free survival; Oncology; Gastroenterology; Cancer; Chemotherapy; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01264611,0.002137199,0.003820434,0.0005322286,0.0007897301,0.00117287,0.0008384938,0.001494787,0.005734052],"category_scores_gemma":[0.007995419,0.0008005824,0.003637955,0.0004960551,0.001007972,0.001255438,0.0006104876,0.002477721,0.0008748632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008794842,"about_ca_system_score_gemma":0.002412521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005493179,"about_ca_topic_score_gemma":0.001390304,"domain_scores_codex":[0.9964107,0.002410926,0.0002168583,0.0003304995,0.0002581566,0.0003729186],"domain_scores_gemma":[0.9945906,0.002179768,0.001238519,0.0007605631,0.0003920509,0.0008384486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9779125,0.004823059,0.003050909,0.0001855769,0.001731139,0.00005266162,0.00005262969,0.0008347084,0.002052075,0.00006131303,0.0009626814,0.008280749],"study_design_scores_gemma":[0.7489224,0.2180631,0.02227048,0.0000443891,0.004386223,0.0001212418,0.00005169045,0.001708243,0.002446376,0.000356881,0.001581513,0.00004745567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743937,0.002422265,0.004290743,0.0005949037,0.000564329,0.008299198,0.006046591,0.0002913894,0.003096884],"genre_scores_gemma":[0.9692496,0.0007835355,0.006614752,0.0009945057,0.0002378479,0.01156194,0.006797591,0.00009764974,0.003662609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01264611,"threshold_uncertainty_score":0.06687981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123602644794425,"score_gpt":0.4753578184967258,"score_spread":0.3629975540172833,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}